Exploratory secondary analysis of the OPTIMA trial (272 adults with opioid use disorder): week-24 retention appeared lower in females than males on both buprenorphine/naloxone (11.6% vs 28.4%) and methadone (26.0% vs 38.1%); no treatment effect on opioid use in either sex.
Secondary analysisn = 272
McAnulty et al. Sex-based effectiveness in buprenorphine/naloxone and methadone treatment for opioid use disorder: Findings from the OPTIMA trial